Evidence map›Paper›PMID 33737296›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2021

Genetically Inferred Telomere Length and Testicular Germ Cell Tumor Risk.

Derek W Brown, Qing Lan, Nathaniel Rothman, John Pluta, Kristian Almstrup, Marlene D Dalgaard, Mark H Greene, Tom Grotmol, Chey Loveday, Stephen M Schwartz and 7 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 11 institutions in 5 countries.

Derek W BrownDivision of Cancer Epidemiology and Genetics, NCI, Rockville, Maryland. derek.brown@nih.gov.ORCID 0000-0001-8393-1713
Qing LanDivision of Cancer Epidemiology and Genetics, NCI, Rockville, Maryland.ORCID 0000-0002-0888-8839
Nathaniel RothmanDivision of Cancer Epidemiology and Genetics, NCI, Rockville, Maryland.
John PlutaDivision of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Kristian AlmstrupDepartment of Growth and Reproduction, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.ORCID 0000-0002-1832-0307
Marlene D DalgaardDepartment of Health Technology, Technical University of Denmark, Kgs. Lyngby, Denmark.
Mark H GreeneDivision of Cancer Epidemiology and Genetics, NCI, Rockville, Maryland.ORCID 0000-0003-1852-9239
Tom GrotmolDepartment of Research, Cancer Registry of Norway, Oslo, Norway.
Chey LovedayDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, England, United Kingdom.ORCID 0000-0002-2291-372X
Stephen M SchwartzEpidemiology Program, Fred Hutchinson Cancer Research Center, Seattle, Washington.ORCID 0000-0001-7499-8502
Clare TurnbullDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, England, United Kingdom.
Fredrik WiklundDepartment of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.ORCID 0000-0002-4623-0544
Peter A KanetskyDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.ORCID 0000-0002-5567-9618
Katherine L NathansonDivision of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0002-6740-0901
Katherine A McGlynn
Mitchell J MachielaDivision of Cancer Epidemiology and Genetics, NCI, Rockville, Maryland.ORCID 0000-0001-6538-9705
Testicular Cancer Consortium
Cancer Genetics (United States) · USTranslational Therapeutics (United States) · USCancer Registry of Norway · NOCancer Research UK · GBCopenhagen University Hospital · DKKarolinska Institutet · SEMoffitt Cancer Center · USPrevention Group · USQueen Mary University of London · GBTechnical University of Denmark · DKUniversity of Washington · US

Funding

UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Robert H. Vonderheide · 1985 to 2026
$222.3M
Hormone-Related CancersZIACP010126 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI GIERACH, GRETCHEN · 2009 to 2025
$103.5M
Translational Research Support CoreP30ES013508 · NIEHS · UNIVERSITY OF PENNSYLVANIA · PI Trevor M Penning · 2006 to 2026
$35.3M
Genetic EpidemiologyZIACP005803 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI GOLDSTEIN, ALISA · 2009 to 2025
$24.8M
Post GWA Studies in Testicular Germ Cell TumorsU01CA164947 · NCI · UNIVERSITY OF PENNSYLVANIA · PI KANETSKY, PETER A, NATHANSON, KATHERINE L. · 2012 to 2024
$11.7M
MOLECULAR EPIDEMIOLOGY OF TESTICULAR CARCINOMAR01CA085914 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI SCHWARTZ, STEPHEN M · 2000 to 2009
$8.4M
Inherited genetic variation and predisposition to testicular germ cell tumorR01CA114478 · NCI · UNIVERSITY OF PENNSYLVANIA · PI NATHANSON, KATHERINE L. · 2007 to 2011
$3.1M
SURVEILLANCE EPIDEMIOLOGY &END RESULTS PROGRAMN01CN067009 · CN · FRED HUTCHINSON CANCER RESEARCH CENTER · PI THOMAS, DAVID B · 1996 to 1997
–
Intramural NIH HHS ZIA CP010126NCI NIH HHS N01 CN067009NCI NIH HHS N01 PC035142NCI NIH HHS P30 CA016520NCI NIH HHS R01 CA085914NCI NIH HHS R01 CA114478NCI NIH HHS U01 CA164947NIEHS NIH HHS P30 ES013508
6 · The paper itself

Abstract

backgroundStudies evaluating the association between peripheral blood leukocyte telomere length (LTL) and testicular germ cell tumor (TGCT) risk have produced conflicting results.

methodsUsing available genotype data from the Testicular Cancer Consortium (TECAC), polygenic risk score and Mendelian randomization analyses of genetic variants previously associated with LTL were used to assess potential etiologic associations between telomere length and TGCT risk.

resultsGenetically inferred telomere length was not associated with TGCT risk among 2,049 cases and 6,921 controls with individual-level genotype data (OR, 1.02; 95% confidence interval, 0.97-1.07). Mendelian randomization analyses using summary statistic data further indicated no evidence for an association between telomere length and TGCT risk among all available TECAC participants (3,558 cases and 13,971 controls).

conclusionsOur analyses in the largest molecular genetic testicular cancer study to date provide no evidence for an association between genetically inferred peripheral blood LTL and TGCT risk. IMPACT: The lack of evidence for an overall association indicates that peripheral blood LTL is likely not a strong biomarker for TGCT risk.

Indexed as

Case-Control StudiesGenetic Predisposition to DiseaseHumansMaleMendelian Randomization AnalysisNeoplasms, Germ Cell and EmbryonalRisk AssessmentRisk FactorsTelomereTelomere HomeostasisTesticular Neoplasms

Identifiers

PMID33737296
PMCPMC8172526
OpenAlexW3136894865

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.